Moderna, Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bullish +50

Hantavirus: Is there a risk of another pandemic?

AI-generated analysis

📈 Moderna shares surged 13% following news of a Hantavirus outbreak on cruise ship MV Hondius involving 10 infections and 3 deaths.

⚠️ Bernstein Global Research downplays pandemic risk, maintaining a Market-Perform rating with a $45 price target implying 17% downside from recent highs.

🦠 The lethal Andes strain of Hantavirus on the ship has demonstrated human-to-human transmission, unlike standard strains spread by rodent contact.

🧬 Moderna is well-positioned to pivot to Hantavirus countermeasures using its scalable mRNA platform with existing research partnerships.

💰 Developing a comprehensive multi-strain vaccine would require $500+ million in Phase 1-3 clinical trials with no immediate consumer rollout expected.

🏛️ Future commercial returns are projected as steady government funding for state stockpiling rather than mass market sales.

📊 Moderna beat first-quarter revenue estimates, posting $389 million compared to analysts' expectations of roughly $228 million.

🌍 International revenue drove growth to $311 million versus $78 million domestically as partnerships in the UK and Australia strengthened.

💼 CFO Jamey Mock stated the company aims for a balanced international vs. U.S. revenue story by 2026 amid shifting vaccine policies.

📅 FDA approval is expected for Moderna's mRNA-based flu vaccine on August 5 after resolving prior trial design disputes.

🎯 The company is expanding into new therapies with late-stage dates expected for norovirus vaccines, a cancer vaccine, and metabolic disorder treatments.

⚖️ RBC Capital notes full-year revenue will be weighted toward the back half, with an anticipated second-quarter range of $50 million to $100 million.

💸 Q4 net loss of $3.40 per share included $2.22 in charges from settling patent disputes over lipid nanoparticle technology.

⚔️ German biotech CureVac sued Moderna in Delaware federal court alleging Spikevax infringed on patents related to mRNA stabilization technology.

🏢 BioNTech, which acquired CureVac last year, also filed a separate lawsuit against Moderna regarding its next-generation mNEXSPIKE COVID-19 shot.

Bullish Signals
  • Moderna Inc (NASDAQ:MRNA) shares rallied 13% over a multi-day period following reports of a localized Hantavirus outbreak aboard the cruise vessel MV Hondius.
Risk Factors
  • Bernstein analysts downplayed pandemic risk, noting Hantavirus outbreaks are highly localized and unlikely to mirror the COVID-19 trajectory, suggesting current market enthusiasm may be short-lived.
  • Bernstein reiterated a Market-Perform rating with a price target of $45.00, implying a 17% downside from Moderna's May 8 closing price of $54.35.
  • Any successful Hantavirus countermeasures would likely result in steady government funding for stockpiling rather than mass consumer rollout, limiting near-term commercial returns.
  • Development of a comprehensive multi-strain vaccine could require phase 1 through phase 3 clinical trials with estimated expenditures exceeding $500 million, creating significant financial risk before any commercial gains.
  • Sweeping changes to U.S. vaccine policy under Health Secretary Robert F. Kennedy Jr. have led to reduced vaccine use and reshaped the regulatory landscape for companies developing new shots, introducing uncertainty into the U.S. market.
  • Moderna expects 2026 revenue growth of up to 10%, but first-half 2025 revenue is weighted at only 15% compared to a much higher second half, indicating significant front-loaded volatility risk.
  • Q1 net loss per share was $3.40 versus analyst estimates of a loss of $3.96, though this included one-time charges that may impact underlying earnings visibility.
  • Moderna faced a patent dispute with Roivant Sciences and Arbutus Biopharma, incurring $2.22 per share in settlement charges related to lipid nanoparticle technology.
  • German biotech company CureVac sued Moderna in Delaware federal court alleging that the Spikevax COVID-19 vaccine infringed on mRNA technology patents, adding potential litigation risk and royalty exposure.
Full Analysis
Investing.com reports that Moderna (MRNA) shares jumped 13% following news of a Hantavirus outbreak aboard the cruise ship MV Hondius, though research from Bernstein Global Research suggests this stock move may be short-lived. The localized outbreak infected roughly 10 passengers and crew with the Andes strain, which has shown human-to-human transmission unlike standard strains, resulting in three deaths. Bernstein maintained its Market-Perform rating with a price target of $45.00, implying 17% downside from May 8's closing price of $54.35. Analysts caution that the localized transmission makes a global pandemic unlikely, and while Moderna is technically capable of pivoting to Hantavirus countermeasures due to its scalable mRNA platform, these collaborations are currently in preclinical stages with no commercially approved vaccines for Hantavirus Cardio-Pulmonary Syndrome (HCPS). Developing such vaccines would require Phase 1 through Phase 3 trials costing over $500 million. Reuters reports that Moderna exceeded Wall Street revenue estimates for the first quarter, driven by better-than-expected international COVID-19 vaccine sales. International revenue reached $311 million compared to $78 million in the U.S., helping first-quarter revenue more than triple to $389 million from a year earlier, surpassing the analyst estimate of nearly $228 million. Chief Financial Officer Jamey Mock noted the company is transitioning to a more balanced global revenue story and expressed hope that regulatory uncertainty under Health Secretary Robert F. Kennedy Jr. has diminished. The company secured an August 5 FDA decision date for its mRNA-based flu vaccine after resolving a previous dispute, with plans to expand into norovirus vaccines, individualized cancer vaccines with partner Merck, and treatments for rare metabolic disorders. Moderna reiterated its 2026 revenue growth forecast of up to 10%, expecting roughly half of total revenue from the U.S., down from 62% last year. The company expects second-quarter revenue between $50 million and $100 million, evenly split between domestic and international markets, while posting a net loss per share of $3.40 versus an analyst estimate of $3.96. This loss included $2.22 per share in charges related to settling a patent dispute over lipid nanoparticle technology with Roivant Sciences' unit Genevant and Arbutus Biopharma. Additionally, German biotech company CureVac sued Moderna in Delaware federal court alleging that the COVID-19 vaccine Spikevax infringed on mRNA stabilizing patents, seeking royalties from sales. BioNTech, which acquired CureVac, also filed a separate patent lawsuit against Moderna in February regarding its next-generation mNEXSPIKE shot.